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INTRODUCTION
In 2019, approximately 330,000 new cases of breast cancer are 
estimated to be diagnosed, with about 80% of those likely to be the 
invasive breast cancer type.1 On average, 75% of all newly diagnosed 
breast cancers are hormone receptor-positive (HR+).2 Although 
HR+ breast cancer expresses both estrogen and progesterone recep-
tors (ER; PR), ER signaling pathways ultimately determine cellular 
growth and survival.3 As a result, drug therapies were developed 
that selectively target vital steps in this ER signaling pathway and 
historically have been the foundation of HR-positive breast cancer 
treatment. As a group, these agents are termed endocrine therapy 
and include aromatase inhibitors (e.g., letrozole, anastrozole, and 
exemestane), selective ER modulators (tamoxifen), and selective ER 
down-regulators (fulvestrant). 
Endocrine therapy alone has its limitations. Not only do certain 
breast cancer patients have inherent estrogen hormone resistance, 
but also HR+ tumor cells have the capability to use alternate, non-
estrogen dependent pathways for further growth and survival.4,5 
One such known alternate route is the cyclin D-cyclin-dependent 
kinase 4/6 (CDK4/6)-inhibitor of CDK4-retinoblastoma pathway.6 
Recently, CDK4/6-inhibitors have been developed and investigated 
to be used alone or with traditional endocrine therapy for HR+ breast 
cancer.7-12
Palbociclib is an oral selective inhibitor of CDK4/6. This novel 
agent was awarded accelerated approval by the US Food and Drug 
Administration (FDA) in 2015 following the PALOMA-1 trial data 
showing that the combination of palbociclib with letrozole results in 
improved progression-free survival rates in metastatic, ER+, human 
epidermal growth factor receptor 2 (HER2)-negative postmeno-
pausal breast cancer patients who had not had prior treatment for 
advanced disease. Subsequently, based on PALOMA-3 trial results, 
palbociclib also was approved for advanced breast cancer refractory 
to endocrine therapy when used in combination with fulvestrant.7, 
14-18 This report presents a rare clinical case of fatal acute liver failure 
following administration of the novel CDK4/6-inihibor, palbociclib. 
CASE REPORT
A 79-year-old female presented to the emergency department with 
acute encephalopathy and jaundice. Her past medical history was 
notable for stage IV invasive ductal carcinoma of the breast with bone 
metastasis, ER+, PR+, HER2– by fluorescence in situ hybridization 
(FISH), who failed initial standard of care chemotherapy, and was 
started on palbociclib and fulvestrant (1st cycle: oral palbociclib 125 
mg oral daily for days 1-21 of a 28-day cycle plus 7-day rest; 2nd cycle: 
oral palbociclib 100 mg daily for days 1-21 of  a 28-day cycle plus 7-day 
rest; intramuscular fulvestrant 500 mg on days 1, 15, and 29). In addi-
tion, her chronic medical conditions included type 2 diabetes mellitus, 
hyperlipidemia, and gastric esophageal reflux disease which were being 
managed with metformin 500 mg daily, atorvastatin 10 mg daily, and 
omeprazole 20 mg daily, respectively. 
The patient had completed her second cycle approximately one 
week prior to presentation. On admission, liver injury was evident 
based on lab results showing a total bilirubin of 4.6 mg/dl (1.0 mg/dl 
one month prior), aspartate transaminase of 200 u/l (AST, 50 u/L 
one month prior), alanine transaminase of 50 u/l (ALT 20 one month 
prior), alkaline phosphatase of 150 u/l (90 u/L one month prior), 
INR of 3.8, and ammonia of 70 u/L. Serum analysis was negative for 
elevated acetaminophen. A thorough autoimmune serology and viral 
hepatitis workup for other possible causes of liver injury was non-
revealing. Thrombocytopenia and macrocytic anemia with equivocal 
support for hemolysis was present based on platelets of 35 x109/L, 
hemoglobin of 8.5 g/dL, mean corpuscular volume of 124 fL, lactic acid 
dehydrogenase of 940U/L (450 one month prior), fibrinogen of 170 
mg/dL; D-dimer of 11,000 ng/mL, undetectable haptoglobin levels, 
and presence of schistocytes on peripheral smear analysis. Infectious 
workup revealed WBC of 7.5 x109/L, 22% bands, 1 of 2 blood cultures 
positive for pansensitive Escherichia coli.  
 Roussel Uclaf Causality Assessment Method (RUCAM)19,20 and 
Drug-Induced Liver Injury Network (DILIN)21 severity scores for pal-
bociclib were 8 (probable) and 5+ (fatal), respectively. Biochemically, 
the liver injury was cholestatic (R factor of 0.2) with a marked increase 
in total bilirubin suggestive of bland cholestasis. Imaging studies 
showed a homogenously enlarged and lobulated liver surrounded 
by perihepatic free fluid. The right liver lobe tip extended inferiorly 
beyond the right kidney suggesting significant hepatomegaly (Figure 1). 
The gallbladder and biliary ducts were unremarkable. These findings 
were notable when compared to CT images of the abdomen performed 
two-years prior which was negative for hepatomegaly, cirrhosis, or a 
lobular appearance. Based on the patient’s clinical history, presenta-
tion, and sonography, acute livery injury was more probable. 
Despite standard of care therapies and steroids she developed 
refractory hypotension, her labs and encephalopathy worsened, and 
her overall condition deteriorated. The patient’s liver enzymes and 
bilirubin continued to trend up: AST of 1268 u/l, ALT of 167 u/l, and 
total bilirubin of 9.8 u/l. The patient subsequently received supportive 
treatment and transitioned to comfort care. 
DISCUSSION
HR+ breast cancer treatment guidelines support the combination 
of CDK-inhibitor plus endocrine therapy based on randomized control 
trial data showing that when used together these therapies are effec-
tive, delay tumor progression, and improve the rates of progression-free 
survival and overall survival.7-12 In the large clinical trials, adverse events 
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cations. However, there have been few case reports of clinically severe 
liver injury attributable to palbociclib. 
Figure 1. Ultrasound, liver. Left image: Homogenously enlarged liver with a 
grossly nodular and lobular appearance (arrows). Right image: Significant 
hepatomegaly represented by liver tip extending inferiorly beyond the level of 
the kidney, ascites (arrows).
Targeted therapies have revolutionized the landscape of oncologic 
treatments. Several studies have evaluated the safety and efficacy of pal-
bociclib in combination with endocrine therapy. Elevated liver function 
tests were a rare but reported adverse event (AE) in 7.2% of the palbo-
ciclib-treated patients in the PALOMA-1 study.22 In the PALOMA-2 
study, ALT and AST elevations were reported as AEs (all grades) in 
9.9% and 9.7% of palbociclib-treated patients, respectively.14 In the 
PALOMA-3 study, there was one fatal serious AE of hepatic failure 
with grade 5 disease progression in the palbociclib group; however, 
the patient’s medical history included progressive liver metastasis and 
disease progression.8 Across all PALOMA studies, a pooled safety anal-
ysis demonstrated that grade 3/4 AST and ALT elevations occurred 
in 3.3% and 2.3% of palbociclib-treated patients, respectively, again 
highlighting a reported but rare occurrence.23
Among all three PALOMA trials, neutropenia was the most frequent-
ly reported adverse reaction.7,14,16 Combination therapy of palbociclib 
with either letrozole or fulvestrant uncommonly resulted in grade 3 
or 4 serious adverse events. The most frequently reported serious 
adverse reactions in patients who received palbociclib plus fulvestrant 
were infections, neutropenia, and pulmonary embolism.16 Among the 
1,348 patients enrolled in the three PALOMA trials, none experienced 
fulminant hepatotoxicity that lead to stopping drug therapy. In the 
intention-to-treat populations, six cases of elevated AST (n = 1, 1%), 
ALT (n = 3, 1%), γ-glutamyl transferase (GGT, n = 2, 2%) were observed 
when palbociclib was administered in combination with letrozole.7,14 
Ascites of any grade (n = 3, 1.7%) was noted for patients receiving dual 
therapy of palbociclib plus fulvestrant.16 Thus, overall few treatment-
related acute liver injuries were observed. However, final trial analysis 
of palbociclib plus fulvestrant noted one liver-related death that was not 
attributed to palbociclib.7 Moreover, the diagnosis of drug-induced liver 
injury remains challenging. 
DILIN causality assessment process, despite its shortcomings, 
remains an important method in the field and a reasonable diagnostic 
standard.21 The mechanism of palbociclib-induced liver enzyme eleva-
tion is not well understood. Palbociclib is metabolized predominately 
by the hepatic CYP3A4 pathway. Thus, liver injury could be caused by 
the production of a toxic or immunogenic intermediate. Equally plausi-
ble, is coadministration with a strong CYP3A inhibitor, which increases 
the plasma exposure of palbociclib. 
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Open source software and databases show there would be a low 
likelihood of clinically significant drug-drug interactions between any 
of the patient’s home medications and palbociclib. However, atorv-
astatin, metformin, and omeprazole are all CYP3A4 substrates and 
possible inhibitors. Thus, palbociclib metabolism theoretically could 
be inhibited causing increased serum concentrations of the substance. 
Currently, there is no official monitoring guidelines in terms of liver 
function testing when a patient is administered palbociclib therapy. 
Likely based on PALOMA trial data, the palbociclib’s FDA-approved 
product monograph only recommends monitoring for neutropenia 
by complete blood counts prior to starting palbociclib therapy, at the 
beginning of each cycle, and on day 14 of the first two cycles, as well as 
clinically indicated.24 No dose adjustment is required for patients with 
mild or moderate hepatic impairment. However, the recommended 
dose of palbociclib for patients with severe hepatic impairment (Child-
Pugh class C) is 75 mg once daily. The patient detailed in this case had 
no history of hepatic impairment prior to starting treatment. Also, her 
liver function testing was unremarkable during assessments between 
cycles one and two of drug therapy. 
In conclusion, the patient described in this case report illustrated 
an uncommon but serious complication from palbociclib in the treat-
ment of metastatic breast cancer. Palbociclib should be considered as 
a possible cause of drug-induced liver injury when targeted CDK 4/6–
based regimens are used.23 Serum aminotransferase elevations above 
3-to-5 times the upper limit of normal or any elevations accompanied 
by jaundice should alarm physicians and lead to temporary or perma-
nent cessation of palbociclib therapy.
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